A strong team

Well-known founders, convinced investors and research-strong employees: Together we are advanceCOR GmbH.

The beginnings

advanceCOR exists since June 2012 and emerged from Corimmun GmbH, which was sold to Janssen Cilag GmbH/Johnson & Johnson. The founding team includes well-known scientists, who still actively shape the course of advanceCOR today.

  • Prof. Dr. Götz Münch, internist and cardiologist, managing director of advanceCOR GmbH.

  • Prof. Dr. Martin Ungerer, internist and cardiologist, head of the medical division of ISAR Bioscience GmbH, member of the Translational Research Group of the German Centre for Cardiovascular Research (DZHK).
  • Prof. Dr. Meinrad Gawaz, Medical Director, Medical Clinic III, Department of Cardiology, University Hospital Tübingen.

  • Prof. Dr. Martin Lohse, Pharmacologist, University of Würzburg, Chairman of ISAR Bioscience GmbH and President of the German Society of Natural Scientists and Physicians (GDNÄ).



Our team

We are a small company with twenty competent, committed employees. Our scientists come from the fields of medicine, pharmacy, biology and chemistry and have a lot of experience in the biotech industry. We are convinced of our pipeline and do everything we can to bring it from research to the bedside.


Prof. Dr. Götz Münch

Managing Director,
Internist and cardiologist

Götz Münch is co-founder and managing director of advanceCOR GmbH, Martinsried, a biotech company that develops personalised cardiovascular drugs. Previously, he was co-founder and managing director of Corimmun GmbH, which was sold to Johnson & Johnson in 2012. Prior to that, he founded and managed ProCorde GmbH – from its successful merger with the British biotech company Trigen until his retirement in 2006. After completing his doctorate under Professor Klaus Starke at the Pharmacological Institute of the University of Freiburg and at University College London under Professor Geoffrey Burnstock in 1992, Götz Münch habilitated in pharmacology at the University of Würzburg in 2004. Since 2012 he has been an associate professor at the Julius Maximilian University of Würzburg. Münch is a specialist in internal medicine and cardiology and a lecturer in biomedicine at the University of Würzburg, where he has taught physiology/pathophysiology since 2001.

Dr. Kerstin Uhland

Operations manager,

Kerstin Uhland is Chief Operating Officer at advanceCOR GmbH. As Operations Manager, she has been pushing forward the further development of the main project Revacept since the company was founded in 2012 and since 2015 also the development of new anti-GPVI-Fabs. She coordinates internal activities as well as external cooperations. In addition, Kerstin Uhland is head of quality assurance in the GLP area. She previously held this position at Corimmun GmbH. From 2001 to 2008, Kerstin Uhland worked as a scientist at Curacyte AG, first in due diligence and later in project management for the preclinical development of serine protease inhibitors for use in oncology and haematology. Previously, she developed analysis kits of protein-DNA interactions for the company Larova GmbH up to market maturity. Kerstin Uhland studied biology at the University of Konstanz and received her PhD in microbiology, genetics and biochemistry in 1998.

Dr. Hans-Peter Holthoff

Scientific director,

Hans-Peter Holthoff is scientific director and head of testing at advanceCOR GmbH in Martinsried near Munich. He previously held the same position at the biotech company Corimmun GmbH from 2007 to 2012. From 2000 to 2006 he worked for the biotech company ProCorde GmbH/Trigen GmbH. Prior to obtaining his doctorate in 2000 from the University of Constance, Hans-Peter Holthoff graduated in biochemistry from the University of Würzburg.

Our investors